Aperture Sectors › Healthcare & Life Sciences › Clinical trials & research operations
Clinical trials & research operations funding
Clinical trials & research operations
A sub-sector of Healthcare & Life Sciences. Each company counts once, in its main sub-sector.
74 rounds, $2.3B raised by 58 companies, Jan 2, 2023 to Nov 14, 2026, 5% of Healthcare & Life Sciences capital. Top three companies: Pathos AI 29%, Formation Bio 16%, Truveta 14%.
| Company | HQ | Capital raised | Rounds | Exit |
|---|---|---|---|---|
| Pathos AI | United States | $664M | 3 | — |
| Formation Bio | United States | $372M | 1 | — |
| Truveta | United States | $320M | 1 | — |
| Paradigm Health | United States | $78M | 1 | — |
| Iterative Health | United States | $77M | 1 | — |
| Lindus Health | United Kingdom | $73M | 2 | — |
| Unlearn | United States | $65M | 2 | — |
| QuantHealth | Israel | $60M | 3 | — |
| Biorce | Spain | $58M | 2 | — |
| PhaseV | Israel | $50M | 1 | — |
| Faro AI | United States | $37M | 1 | — |
| Triomics | United States | $37M | 2 | — |
| Atropos Health | United States | $33M | 1 | — |
| Altis Labs | Canada | $31M | 2 | — |
| Pi Health | United States | $30M | 1 | — |
| Ingenix | Poland | $25M | 2 | — |
| Condor Software | United States | $24M | 1 | — |
| Medeloop | United States | $24M | 2 | — |
| Qureight | United Kingdom | $20M | 1 | — |
| Weave | United States | $20M | 1 | — |
| Rivia | Switzerland | $18M | 2 | — |
| Novellia | United States | $18M | 1 | — |
| Cognivia | Belgium | $17M | 1 | — |
| Graph AI | United States | $16M | 2 | — |
| Revalia Bio | United States | $14M | 1 | — |
| Company | Amount | Stage | Announced |
|---|---|---|---|
| Formation Bio | $372M | Series D | Jun 26, 2024 |
| Pathos AI | $365M | Series D | May 15, 2025 |
| Truveta | $320M | Unlabeled | Jan 13, 2025 |
| Pathos AI | $237M | Series E | Oct 23, 2026 |
| Paradigm Health | $78M | Series B | Dec 4, 2025 |
| Iterative Health | $77M | Series C | Apr 30, 2026 |
| Pathos AI | $62M | Series C | Oct 29, 2024 |
| Lindus Health | $55M | Series B | Jan 22, 2025 |
| Biorce | $52M | Series A | Feb 2, 2026 |
| PhaseV | $50M | Series A | May 13, 2025 |